
Board Meeting19 Oct 2026, 03:48 pm
Marksans Pharma Board Meeting on Nov 4 to Approve Unaudited Results
AI Summary
Marksans Pharma Ltd has announced that its Board of Directors will convene on November 4, 2026, to consider and approve the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. The results will be presented on both a standalone and consolidated basis. Concurrently, the company has closed its trading window for designated persons from October 1, 2026, until 48 hours after the financial results announcement, expected to be November 6, 2026. This intimation will be available on the company's and stock exchanges' websites.
Key Highlights
- Board meeting scheduled for November 4, 2026.
- To approve Unaudited Financial Results for Q2 FY27.
- Results to be presented on standalone and consolidated basis.
- Trading window closed from October 1 to November 6, 2026.
- Intimation available on company and exchange websites.
Price Impact
More from MARKSANS